These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 498106)

  • 1. Cellular cytotoxicity and serum inhibition in normal mice following transfer of xenogeneic tumor-sensitized cells.
    Fisher B; Wolmark N; Saffer EA
    Cancer Res; 1979 Dec; 39(12):4772-6. PubMed ID: 498106
    [No Abstract]   [Full Text] [Related]  

  • 2. Cellular cytotoxicity in tumor-bearing mice after transfer of normal or tumor-sensitized lymphoid cells.
    Fisher B; Wolmark N; Saffer EA
    J Natl Cancer Inst; 1980 Dec; 65(6):1303-5. PubMed ID: 6933275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular cytotoxicity and serum inhibition in normal mice following transfer of syngeneic tumor-sensitized cells.
    Fisher B; Wolmark N; Saffer EA
    J Natl Cancer Inst; 1980 Mar; 64(3):579-85. PubMed ID: 6986497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor specificity, serum inhibition, and influence of regional lymph nodes on cytotoxic macrophages from cultured bone marrow.
    Fisher B; Hanlon JT; Linta J; Saffer E
    Cancer Res; 1977 Oct; 37(10):3628-33. PubMed ID: 908011
    [No Abstract]   [Full Text] [Related]  

  • 5. Enhanced immune reactivity to hepatoma 22a cells in MTV-infected compared with MTV-free C3H mice.
    Lavrovsky VA; Viksler VK
    Immunology; 1981 Dec; 44(4):671-6. PubMed ID: 6274791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy of murine mammary carcinoma using broadly cytotoxic cloned T lymphocytes.
    Salup RR; Toth JA; Hiserodt JC; Wolmark N
    Prog Clin Biol Res; 1987; 244():39-48. PubMed ID: 2958875
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation of antitumor chemoimmunotherapy with serum inhibition of tumor cell destruction.
    Fisher B; Hanlon J; Gebhardt M; Linta J; Saffer E
    Cancer Res; 1978 Jan; 38(1):38-41. PubMed ID: 618581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic adoptive transfer of immunity to 13762A rat mammary adenocarcinoma.
    Boyer CM; Kreider JW; Bartlett GL
    Cancer Res; 1981 Jun; 41(6):2394-400. PubMed ID: 6972251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of murine tumor with syngeneic antitumor serum plus BCG.
    Yamazaki M; Saito M; Abe S; Mizuno D
    Jpn J Exp Med; 1983 Feb; 53(1):27-32. PubMed ID: 6876475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective serum effects in tumor immunity.
    Vaage J
    Isr J Med Sci; 1976; 12(4-5):334-43. PubMed ID: 939693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune status of autochthonous and adoptively protected mice toward spontaneous and chemically induced tumors.
    Basombrío MA; Prehn RT
    Cancer Res; 1972 Nov; 32(11):2545-50. PubMed ID: 5082598
    [No Abstract]   [Full Text] [Related]  

  • 12. Induction of "innocent bystander" cytotoxicity in nonimmune mice by adoptive transfer of L3T4+ Lyt-1+2- mammary tumor immune T-cells.
    Paul RD; Lopez DM
    Cancer Res; 1987 Feb; 47(4):1105-10. PubMed ID: 2879623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Corynebacterium parvum on cytotoxicity of regional and nonregional lymph node cells from animals with tumors present or removed.
    Fisher B; Wolmark N; Coyle J
    J Natl Cancer Inst; 1974 Dec; 53(6):1793-801. PubMed ID: 4471644
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative effects of Corynebacterium parvum, Brucella abortus extract, Bacillus Calmette-Guérin, glucan, levamisole, and tilorone with or without cyclophosphamide on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model.
    Fisher B; Gebhardt M
    Cancer Treat Rep; 1978 Nov; 62(11):1919-30. PubMed ID: 728912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY; Chou T; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ambiguous action of splenocytes from tumor-bearing mice on the formation of metastases in the lungs of mice in an adaptive transfer system].
    Iunker VM; Arkhipov SA; Gruntenko EV
    Biull Eksp Biol Med; 1984 Nov; 98(11):598-600. PubMed ID: 6509179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic characterization of tumor-associated transplantation antigens on MM102 mammary tumor eliciting preferentially helper T cell activity.
    Fujiwara H; Aoki H; Tsuchida T; Hamaoka T
    J Immunol; 1978 Oct; 121(4):1591-5. PubMed ID: 308971
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of "foreign" alloantigen-like specificities on a murine lymphoma cell line.
    Finke JH; Fyfe DA; Del Villano BC; Butler GH; Ponzio NM
    Transplant Proc; 1980 Mar; 12(1):53-8. PubMed ID: 6154359
    [No Abstract]   [Full Text] [Related]  

  • 20. Mammary tumor virus-associated antigenicity of L-1210 murine leukemia cells.
    Kisielow P; Radzikowski C; Steuden J; Szkudlarek J; Krawczynski K
    Arch Immunol Ther Exp (Warsz); 1971; 19(6):789-99. PubMed ID: 4335186
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.